Clinical Trials
24 trialsNCT03937830 2026-06-05
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT05669339 2026-06-04
AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
University of Florida
Phase 2 Recruiting
NCT02465060 2026-06-03
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02519348 2026-06-03
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
MedImmune LLC
Phase 2 Active not recruiting
NCT07557914 2026-06-03
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
First Hospital of China Medical University
Phase 2 Not yet recruiting
NCT04954339 2026-06-02
DYNAMIC
Asan Medical Center
Phase 2 Completed
NCT05063565 2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2 Active not recruiting
NCT05507632 2026-06-01
Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Active not recruiting
NCT06096779 2026-06-01
Kirros
Genentech, Inc.
Phase 2 Recruiting
NCT02968810 2026-05-29
Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04175912 2026-05-29
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06405061 2026-05-29
Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Suspended
NCT07483359 2026-05-28
CONV3RSION
First Hospital of China Medical University
Phase 2 Recruiting
NCT02867592 2026-05-27
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07495579 2026-05-27
REVIVE
Asan Medical Center
Phase 2 Not yet recruiting
NCT04982653 2026-05-26
Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05620771 2026-05-26
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
Northwestern University
Phase 2 Recruiting
NCT05099848 2026-05-22
A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
Phase 2 Completed
NCT06187961 2026-05-22
CCGLC-011
Tongji Hospital
Phase 2 Active not recruiting
NCT06953089 2026-05-22
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 2 Recruiting
NCT07493668 2026-05-22
FLEX-HCC
CHA University
Phase 2 Recruiting
NCT04123379 2026-05-20
Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT06503146 2026-05-19
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07285044 2026-05-18
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Phase 2 Recruiting